COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

COSCIENS Biopharma Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Capital Expenditures
-$969k
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
-28%
Theratechnologies Inc
TSX:TH
Capital Expenditures
-$10.1m
CAGR 3-Years
-186%
CAGR 5-Years
-86%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Capital Expenditures
-$236k
CAGR 3-Years
-7%
CAGR 5-Years
46%
CAGR 10-Years
-13%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Capital Expenditures
-$1.3m
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
-1%
Spectral Medical Inc
TSX:EDT
Capital Expenditures
-CA$194k
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
3%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Capital Expenditures?
Capital Expenditures
-969k USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Capital Expenditures amounts to -969k USD.

What is COSCIENS Biopharma Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-28%

Over the last year, the Capital Expenditures growth was -13%. The average annual Capital Expenditures growth rates for COSCIENS Biopharma Inc have been -75% over the past three years , and -28% over the past ten years .

Back to Top